CL2008001294A1 - Metodo para la purificacion de un virus o antigeno de un virus mediante gradientes de sacarosa en una ultracentrifuga continua. - Google Patents

Metodo para la purificacion de un virus o antigeno de un virus mediante gradientes de sacarosa en una ultracentrifuga continua.

Info

Publication number
CL2008001294A1
CL2008001294A1 CL2008001294A CL2008001294A CL2008001294A1 CL 2008001294 A1 CL2008001294 A1 CL 2008001294A1 CL 2008001294 A CL2008001294 A CL 2008001294A CL 2008001294 A CL2008001294 A CL 2008001294A CL 2008001294 A1 CL2008001294 A1 CL 2008001294A1
Authority
CL
Chile
Prior art keywords
virus
antigen
purification
sucrose gradients
ultracentrifuge
Prior art date
Application number
CL2008001294A
Other languages
English (en)
Inventor
Manfred Reiter
Leopold Grillberger
Wolfgang Mundt
Artur Mitterer
Horst Schafhauser
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008001294(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of CL2008001294A1 publication Critical patent/CL2008001294A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)

Abstract

Método para la purificación de un virus o antígeno de un virus; método para preparar una vacuna contra un virus o antígeno de virus que comprende un virus o antígeno de virus obtenido de acuerdo al método para la purificación antes mencionado.
CL2008001294A 2007-05-04 2008-05-05 Metodo para la purificacion de un virus o antigeno de un virus mediante gradientes de sacarosa en una ultracentrifuga continua. CL2008001294A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92769207P 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
CL2008001294A1 true CL2008001294A1 (es) 2009-03-06

Family

ID=39596388

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001294A CL2008001294A1 (es) 2007-05-04 2008-05-05 Metodo para la purificacion de un virus o antigeno de un virus mediante gradientes de sacarosa en una ultracentrifuga continua.

Country Status (18)

Country Link
US (4) US20100239609A1 (es)
EP (1) EP2155864B1 (es)
JP (2) JP5745717B2 (es)
KR (4) KR101998537B1 (es)
CN (2) CN101688187A (es)
AR (1) AR066449A1 (es)
AU (1) AU2008248904B2 (es)
BR (1) BRPI0811499B8 (es)
CA (1) CA2687119C (es)
CL (1) CL2008001294A1 (es)
HK (2) HK1138318A1 (es)
IL (1) IL201898A (es)
MX (1) MX2009011897A (es)
PE (1) PE20090284A1 (es)
RU (1) RU2503719C2 (es)
TW (1) TWI472620B (es)
WO (1) WO2008135229A2 (es)
ZA (1) ZA200907743B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239609A1 (en) * 2007-05-04 2010-09-23 Baxter International Inc. Formulation of Sugar Solutions for Continuous Ultracentrifugation for Virus Purification
US20110293660A1 (en) * 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
CN101948813B (zh) * 2010-09-04 2012-07-25 国家海洋局第一海洋研究所 一种刺参球形病毒的分离方法
WO2016096688A1 (en) 2014-12-16 2016-06-23 Glaxosmithkline Biologicals S.A. A method for a large scale virus purification
EP3255054A1 (en) * 2016-06-06 2017-12-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the purification of biological macromolecular complexes
SG11201903890QA (en) * 2016-11-04 2019-05-30 Baxalta Inc Adeno-associated virus purification methods
KR102590519B1 (ko) 2017-03-03 2023-10-17 다케다 야쿠힌 고교 가부시키가이샤 아데노-연관 바이러스 제제의 효력을 결정하는 방법
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法
WO2022229703A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. New aav8 based immune escaping variants
WO2022229702A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. Aav8 capsid variants with enhanced liver targeting
AU2022364731A1 (en) * 2021-10-12 2024-05-02 Cytonus Therapeutics, Inc. Systems and methods for manufacturing of therapeutic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
ATE1882T1 (de) * 1978-05-08 1982-12-15 Merck & Co. Inc. Ein verfahren zur direkten extraktion von kleinen teilchen bis 50 nm aus einer proteinhaltigen fluessigkeit.
US4217418A (en) * 1978-05-08 1980-08-12 Merck & Co., Inc. Recovery of small particles by flow centrifugation
JPH06247995A (ja) * 1991-06-24 1994-09-06 Asahi Chem Ind Co Ltd 新規なシアリル（α２−６）ラクトテトラオシルセラミド
RU2080124C1 (ru) * 1995-10-19 1997-05-27 Санкт-Петербургский научно-исследовательский институт вакцин и сывороток Способ получения живой гриппозной вакцины
ES2377968T3 (es) * 2003-04-01 2012-04-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y composiciones farmacéuticas
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN1739801A (zh) * 2004-08-27 2006-03-01 上海生物制品研究所 一种流行性感冒病毒裂解疫苗及其制备方法
US20100239609A1 (en) * 2007-05-04 2010-09-23 Baxter International Inc. Formulation of Sugar Solutions for Continuous Ultracentrifugation for Virus Purification

Also Published As

Publication number Publication date
BRPI0811499A2 (pt) 2014-10-14
KR101998537B1 (ko) 2019-07-09
US20100239609A1 (en) 2010-09-23
CA2687119C (en) 2021-06-08
US20160060603A1 (en) 2016-03-03
KR101744430B1 (ko) 2017-06-20
KR20170065671A (ko) 2017-06-13
US8969533B2 (en) 2015-03-03
TWI472620B (zh) 2015-02-11
PE20090284A1 (es) 2009-03-17
HK1211320A1 (en) 2016-05-20
TW200914615A (en) 2009-04-01
HK1138318A1 (en) 2010-08-20
WO2008135229A3 (en) 2008-12-31
JP2010525798A (ja) 2010-07-29
AU2008248904A1 (en) 2008-11-13
BRPI0811499B1 (pt) 2019-06-04
CN101688187A (zh) 2010-03-31
US20080274138A1 (en) 2008-11-06
AU2008248904B2 (en) 2014-10-09
KR20180077305A (ko) 2018-07-06
IL201898A (en) 2013-11-28
CN104694489A (zh) 2015-06-10
RU2009144980A (ru) 2011-06-10
WO2008135229A2 (en) 2008-11-13
RU2503719C2 (ru) 2014-01-10
JP2015061538A (ja) 2015-04-02
JP5745717B2 (ja) 2015-07-08
JP6031082B2 (ja) 2016-11-24
IL201898A0 (en) 2011-08-01
KR20150082676A (ko) 2015-07-15
US9732327B2 (en) 2017-08-15
ZA200907743B (en) 2010-09-29
BRPI0811499B8 (pt) 2021-05-25
EP2155864B1 (en) 2013-07-17
MX2009011897A (es) 2010-02-04
KR20100017594A (ko) 2010-02-16
CA2687119A1 (en) 2008-11-13
KR101873891B1 (ko) 2018-07-04
EP2155864A2 (en) 2010-02-24
AR066449A1 (es) 2009-08-19
US20170369853A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
CL2008001294A1 (es) Metodo para la purificacion de un virus o antigeno de un virus mediante gradientes de sacarosa en una ultracentrifuga continua.
SMT201600475B (it) Procedimenti per la preparazione di inibitori di sglt2
BR112013020070A2 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
DK2346888T3 (da) Fremgangsmåde til fremstilling af som SGLT-inhibitorer anvendelige forbindelser
SMT201400079B (it) Produzione di poliovirus ad alti titoli per la produzione di vaccino
CL2014001641A1 (es) Compuestos derivados de nucleosidos sustituidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y uso para mejorar o tratar una infeccion viral.
FR2884255B1 (fr) Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
SMT201400189B (it) Composizione per indurre una rigenerazione tissutale tramite attivazione del plasma ricco di piastrine (prp), e metodo per la sua preparazione
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
CR20120184A (es) Anticuerpos monoclonales frente a progastrina y su usos
CU20130157A7 (es) 4 - aril- n- fenil- 1,3,5- triazin- 2- aminas que contienen un grupo sulfoximina
CR20120011A (es) Inhibidores de bace
BR112012004807A2 (pt) vacina para pcsk9
BRPI1010774A2 (pt) método de uso de particulados.
DOP2010000328A (es) Inhibidores de bace
BR112012017051A2 (pt) método para diminuir a imunogenicidade
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
BRPI0917254A2 (pt) método para remover um tampão, sistema, e aparelho
DK2398817T4 (da) Fremgangsmåde til rensning af lipopeptider
CL2013001129A1 (es) Composicion que comprende una celula madre gbm6-ad de glioblastoma purificada; metodo de generacion de anticuerpos especificos para gbm6-ad; dicho anticuerpo; metodo para producir una vacuna de celulas dendriticas; y su uso para el tratamiento de cancer.
CL2009001298A1 (es) Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4.
EP2351835A4 (en) PROCESS FOR PREPARING CLEANED INFLUENZA VIRUS ANTIGENES
BRPI0917447A2 (pt) vacinas para bronquite infecciosa derivada de cepas similres a ib-qx
BRPI0916732A2 (pt) vacina contra hpv